83-5965-10　Cofetuzumab (PTK7) 100ug　591762

特徴

• Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells.
• Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity.
• Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells.
• Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells.
• Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Cofetuzumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.